IGNAC FOGELMAN; RODNEY G. BESSENT
To the editor: We read with interest the article in the March 1979 issue by McFarlane and associates (1) in which 24-h renal excretion of technetium-99m diphosphonate was used as a measure of the whole-body retention in a patient with osteomalacia. Whole-body retention of diphosphonate at 24 h after injection reflects the total skeletal uptake of tracer and provides a simple method for assessing current skeletal metabolic activity (2). It is therefore of considerable clinical value, but we believe measuring the whole-body retention directly is important, because the accuracy of any urinary collection must always be suspect unless the patient
Learn more about subscription options.
Register Now for a free account.
FOGELMAN I, BESSENT RG. Renal Excretion of Technetium-99m Diphosphonate in Osteomalacia. Ann Intern Med. 1979;91:320–321. doi: 10.7326/0003-4819-91-2-320_2
Download citation file:
Published: Ann Intern Med. 1979;91(2):320-321.
Endocrine and Metabolism, Metabolic Bone Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only